Chemotherapy-Free Treatment with Radiotherapy and Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer.

Area of Science:

• Oncology
• Thoracic Oncology
• Cancer Treatment

Background:

• Standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) involves concurrent chemoradiotherapy (CRT) followed by immunotherapy.
• Many LA-NSCLC patients cannot tolerate CRT due to toxicity or poor health.
• Chemotherapy-free approaches combining radiotherapy (RT) and immunotherapy offer a potentially safer alternative.

Purpose of the Study:

• To review the efficacy and safety of chemotherapy-free regimens combining RT and immunotherapy for LA-NSCLC.
• To explore the role of biomarkers in patient selection for these novel treatment strategies.
• To identify areas for optimization in treatment sequencing and radiation protocols.

Main Methods:

• Comprehensive literature review of studies from 2000-2024 using PubMed, Google Scholar, and conference proceedings.
• Analysis of Phase I/II trials investigating chemotherapy-free RT and immunotherapy in LA-NSCLC.
• Focus on clinical outcomes, biomarker integration, treatment timing, radiation parameters, and safety.

Main Results:

• Promising one-year progression-free survival (PFS) rates from 39% to 76% reported in multiple trials.
• Generally acceptable toxicity, with higher-grade events in older, frail patients.
• Biomarkers like PD-L1, tumor mutational burden (TMB), and circulating tumor DNA (ctDNA) show potential for patient stratification.
• Variations in immunotherapy timing and radiation schedules require further optimization.

Conclusions:

• Chemotherapy-free regimens are a promising strategy for LA-NSCLC patients, particularly those unsuitable for CRT.
• Biomarker-guided patient selection and optimized integration of RT and immunotherapy are crucial for improved outcomes.
• Randomized trials are necessary to confirm the efficacy and safety of these emerging treatments.